Management of Hypertension in Diabetic Patients

Initial Assessment and Treatment

The American Diabetes Association recommends prompt initiation of pharmacologic antihypertensive therapy alongside lifestyle modifications for individuals with confirmed office-based blood pressure ≥160/100 mmHg, with a target blood pressure of <130/80 mmHg 1
For diabetic patients with blood pressure ≥160/100 mmHg, the American Diabetes Association guidelines suggest starting with two drugs, given the high cardiovascular risk 1
The American Heart Association suggests that lifestyle therapy alone is only considered for BP 130-139/80-89 mmHg, and even then only for a maximum of 3 months 2

The American Diabetes Association recommends starting with an ACE inhibitor (or ARB if not tolerated) PLUS a thiazide-like diuretic as the initial two-drug combination 1, 3, 4
ACE inhibitors (e.g., lisinopril 10-20 mg daily) or ARBs (e.g., losartan 50-100 mg daily) are preferred first-line agents in diabetic patients because they reduce cardiovascular events and protect against progressive kidney disease 1, 5, 6
If albuminuria is present (urine albumin-to-creatinine ratio ≥30 mg/g), an ACE inhibitor or ARB is strongly recommended to reduce progression of nephropathy 1, 5, 6

The American Diabetes Association recommends obtaining serum creatinine and estimated GFR to establish baseline kidney function before initiating therapy 1, 6
Serum potassium levels should be checked before starting ACE inhibitor/ARB therapy 1, 6
Urine albumin-to-creatinine ratio should be determined to assess the need for ACE inhibitor/ARB therapy 1, 5, 6

The American Diabetes Association recommends initiating weight loss, DASH-style eating pattern, alcohol moderation, and physical activity alongside medications 1, 7, 8
The American Heart Association suggests aiming for a DASH-style eating pattern with 8-10 servings of fruits/vegetables daily, 2-3 servings of low-fat dairy, and reducing sodium to <2,300 mg/day 1, 7, 8

The American Diabetes Association recommends aiming for a blood pressure target of <130/80 mmHg for most diabetic patients, particularly those with high cardiovascular risk 1, 7, 8
For patients with low cardiovascular risk, older age, frailty, or substantial comorbidities, a less intensive target of <140/90 mmHg is acceptable 7, 8

The American Diabetes Association advises against combining ACE inhibitor + ARB due to increased risk of hyperkalemia, syncope, and acute kidney injury without added cardiovascular benefit 3, 4, 6, 9
The American Heart Association recommends avoiding the use of ACE inhibitor/ARB + direct renin inhibitor due to similar risks without benefit 6, 9

The American Diabetes Association recommends rechecking blood pressure in 2-4 weeks after initiating therapy to assess response 1
Medications should be titrated to maximum tolerated doses if the target blood pressure is not achieved 1, 3